You are here
P&T October 2017
In an effort to control costs, the Centers for Medicare and Medicaid Services wants to exact a severe reduction in reimbursement to hospitals that participate in the 340B Drug Pricing Program. The author discusses the program’s shortcomings, the actions taken to address them, and how participating hospitals might be affected by the cut.
Pharmacists are well suited to improve outcomes by delivering medication therapy management (MTM) services. This article presents an MTM pilot program for patients with uncontrolled diabetes that led to significant reductions in hemoglobin A1c.
While cholera is not endemic in the U.S., many travelers are at risk for this life-threatening infection. The authors focus on the target population, safety, and efficacy associated with the use of the vaccine for the prophylaxis of cholera.
An electronic P&T committee meeting system that encompasses document sharing, voting, and communication can help multisite institutions unify their formularies across multiple sites. The authors describe one such system designed, developed, and implemented in a large health care system in the Middle East.
Analysts have identified several unmet needs in the HIV therapy marketplace. We present the promising candidates in late-stage clinical development or FDA review.
Off-label drug bills are back on track but could run off the rails
Misidentification of alphanumeric symbols plays a role in errors
Approvals, new indications, regulatory activities, and more
L-glutamine oral powder (Endari) for reducing the acute complications of sickle cell disease; edaravone (Radicava) for the treatment of amyotrophic lateral sclerosis; and midostaurin (Rydapt) for the treatment of acute myeloid leukemia in combination with chemotherapy
Xadago (safinamide), a monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson’s disease